![Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial - ScienceDirect Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0140673623009224-gr1.jpg)
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial - ScienceDirect
![Sumanta K. Pal, MD, FASCO on X: "Flawless presentation by @DrChoueiri at #ASCO23 of #CONTACT03 results. We didn't sleep much over the past several weeks putting this manuscript together for simultaneous pub Sumanta K. Pal, MD, FASCO on X: "Flawless presentation by @DrChoueiri at #ASCO23 of #CONTACT03 results. We didn't sleep much over the past several weeks putting this manuscript together for simultaneous pub](https://pbs.twimg.com/media/Fx39GcuWIAEAZ9P.jpg)
Sumanta K. Pal, MD, FASCO on X: "Flawless presentation by @DrChoueiri at #ASCO23 of #CONTACT03 results. We didn't sleep much over the past several weeks putting this manuscript together for simultaneous pub
Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhib
Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhib
![CONTACT-03: underscoring the need to identify new treatment strategies in metastatic renal cancer after disease progression with prior immunotherapy - VHIO CONTACT-03: underscoring the need to identify new treatment strategies in metastatic renal cancer after disease progression with prior immunotherapy - VHIO](https://vhio.net/wp-content/uploads/2023/02/cristina-saurez-web-3-thegem-blog-default.jpg)
CONTACT-03: underscoring the need to identify new treatment strategies in metastatic renal cancer after disease progression with prior immunotherapy - VHIO
![Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial - The Lancet Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial - The Lancet](https://www.thelancet.com/cms/asset/29e1f240-b72a-491f-86ad-19e0573ade9b/gr1.jpg)
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial - The Lancet
![Neeraj Agarwal, MD, FASCO on X: "@Montypal never tires of highlighting and praising others' work but rarely talks about his own accomplishments👉 THREE back-to-back FIRST author @TheLancet papers on original research in Neeraj Agarwal, MD, FASCO on X: "@Montypal never tires of highlighting and praising others' work but rarely talks about his own accomplishments👉 THREE back-to-back FIRST author @TheLancet papers on original research in](https://pbs.twimg.com/media/Fx51aL4agAIVOOV.jpg:large)